Cargando…

The efficacy of maintenance therapy after remission induction with tacrolimus in ulcerative colitis with and without previous tumor necrosis factor‐α inhibitor

BACKGROUND AND AIM: Tacrolimus (TAC) is an important therapeutic option for remission induction in patients with refractory ulcerative colitis (UC). However, there is little evidence available on long‐term outcomes and maintenance treatments after TAC therapy, especially in cases with previous tumor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suzuki, Taketo, Mizoshita, Tsutomu, Tanida, Satoshi, Sugimura, Naomi, Katano, Takahito, Nishie, Hirotada, Kataoka, Hiromi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Publishing Asia Pty Ltd 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6586576/ https://www.ncbi.nlm.nih.gov/pubmed/31276039 http://dx.doi.org/10.1002/jgh3.12140

Ejemplares similares

Combination Therapy With Adalimumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients With Refractory Ulcerative Colitis
por: Tanida, Satoshi, et al.
Publicado: (2015)

Prospective comparison of preference and efficacy of adalimumab and infliximab for treating ulcerative colitis naive to antitumor necrosis factor therapy
por: Mizoshita, Tsutomu, et al.
Publicado: (2017)

Colon Mucosa Exhibits Loss of Ectopic MUC5AC Expression in Patients with Ulcerative Colitis Treated with Oral Tacrolimus
por: Mizoshita, Tsutomu, et al.
Publicado: (2013)

Combination Therapy With Ustekinumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients With Refractory Ulcerative Colitis
por: Tanida, Satoshi, et al.
Publicado: (2021)

Long-Term Efficacy of Adalimumab in Patients With Intestinal Behcet’s Disease: Eight Consecutive Cases
por: Tanida, Satoshi, et al.
Publicado: (2016)

A Complicated Case of Tacrolimus-Induced Rapid Remission after Cesarean Section in the Early Third Trimester for Refractory Severe Ulcerative Colitis Flaring in the Initial Period of Gestation
por: Mizushima, Takashi, et al.
Publicado: (2011)

Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn's Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment
por: Suzuki, Taketo, et al.
Publicado: (2019)

The First Case of Biological Therapy Discontinuation After a Complete Remission Induced by Maintenance Therapy With Adalimumab for Refractory Ulcerative Colitis
por: Tanida, Satoshi, et al.
Publicado: (2015)

Combination Therapy With Tofacitinib Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis as Induction Therapy for Refractory Ulcerative Colitis
por: Tanida, Satoshi, et al.
Publicado: (2020)

Long-Term Clinical Remission in Biologically Naïve Crohn's Disease Patients with Adalimumab Therapy, Including Analyses of Switch from Adalimumab to Infliximab
por: Mizoshita, Tsutomu, et al.
Publicado: (2016)

Managing refractory Crohn’s disease: challenges and solutions
por: Tanida, Satoshi, et al.
Publicado: (2015)

Tacrolimus for Remission Induction and Maintenance Therapy in Patients with Ulcerative Colitis: A Retrospective Evaluation Study
por: Ito, Ayumi, et al.
Publicado: (2016)

Efficacy of Switching to Adalimumab for Maintenance of Remission Following Induction Therapy with Tacrolimus in Patients with Ulcerative Colitis
por: Numa, Keijiro, et al.
Publicado: (2023)

Organizing Pneumonia in a Patient with Quiescent Crohn's Disease
por: Tanida, Satoshi, et al.
Publicado: (2016)

Novel and Simple Criteria for Predicting Mortality of Peptic Ulcer Disease
por: Iwasaki, Hiroyasu, et al.
Publicado: (2021)

Urinary Cysteine-Rich Protein 61 and Trefoil Factor 3 as Diagnostic Biomarkers for Colorectal Cancer()
por: Shimura, Takaya, et al.
Publicado: (2019)

Adalimumab Treatment in Biologically Naïve Crohn's Disease: Relationship with Ectopic MUC5AC Expression and Endoscopic Improvement
por: Mizoshita, Tsutomu, et al.
Publicado: (2014)

5-aminolaevulinic acid (5-ALA) accumulates in GIST-T1 cells and photodynamic diagnosis using 5-ALA identifies gastrointestinal stromal tumors (GISTs) in xenograft tumor models
por: Sasaki, Makiko, et al.
Publicado: (2021)

Successful diagnosis and endoscopic submucosal dissection of a gastric gastrointestinal stromal tumor originating from the submucosal layer
por: Shimura, Takaya, et al.
Publicado: (2022)

Pyostomatitis Vegetans and Pyoderma Gangrenosum after Total Colectomy
por: Ozeki, Keiji, et al.
Publicado: (2022)

Vascular Shutdown by Photodynamic Therapy Using Talaporfin Sodium
por: Suzuki, Taketo, et al.
Publicado: (2020)

Immunogenic cell death due to a new photodynamic therapy (PDT) with glycoconjugated chlorin (G-chlorin)
por: Tanaka, Mamoru, et al.
Publicado: (2016)

Primary Sclerosing Cholangitis and Autoimmune Hepatitis Overlapping Syndrome Complicated by Ulcerative Colitis
por: Suzuki, Takanori, et al.
Publicado: (2022)

The Risk Analyses of Lymph Node Metastasis and Recurrence for Submucosal Invasive Colorectal Cancer: Novel Criteria to Skip Completion Surgery
por: Ozeki, Takanori, et al.
Publicado: (2022)

Rapid Induction and Maintenance of Remission in Refractory Ulcerative Colitis with Ustekinumab
por: Chen, An-Yu, et al.
Publicado: (2019)

Successful remission of ulcerative colitis flare-up during pregnancy with adsorptive granulomonocytapheresis plus tacrolimus
por: Shibuya, Tomoyoshi, et al.
Publicado: (2018)

Therapeutic Effects of Biobran, Modified Arabinoxylan Rice Bran, in Improving Symptoms of Diarrhea Predominant or Mixed Type Irritable Bowel Syndrome: A Pilot, Randomized Controlled Study
por: Kamiya, Takeshi, et al.
Publicado: (2014)

Involvement of oxidative stress and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in inflammatory bowel disease
por: Tanida, Satoshi, et al.
Publicado: (2011)

Mechanisms of Cisplatin-Induced Apoptosis and of Cisplatin Sensitivity: Potential of BIN1 to Act as a Potent Predictor of Cisplatin Sensitivity in Gastric Cancer Treatment
por: Tanida, Satoshi, et al.
Publicado: (2012)

Tacrolimus for the Treatment of Ulcerative Colitis
por: Matsuoka, Katsuyoshi, et al.
Publicado: (2015)

Retrospective investigation of tacrolimus combined with an anti‐tumor necrosis factorα antibody as remission induction therapy for refractory ulcerative colitis: Efficacy, safety, and relapse rate
por: Ito, Ayumi, et al.
Publicado: (2019)

The earliest trough concentration predicts the dose of tacrolimus required for remission induction therapy in ulcerative colitis patients
por: Hiraoka, Sakiko, et al.
Publicado: (2015)

Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis
por: Naganuma, Makoto, et al.
Publicado: (2021)

Induction Therapy With a Combination of Weekly Adalimumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis in Patients With Ulcerative Colitis and Failure of Conventional Agents, Biologics and Janus Kinase Inhibitor
por: Tanida, Satoshi, et al.
Publicado: (2023)

Combination Therapy with Intensive Granulocyte and Monocyte Adsorptive Apheresis plus Adalimumab: Therapeutic Outcomes in 5 Cases with Refractory Crohn's Disease
por: Ozeki, Keiji, et al.
Publicado: (2012)

Comparative efficacy of antitumor necrosis factor agents and tacrolimus in naïve steroid-refractory ulcerative colitis patients
por: Kitayama, Moto, et al.
Publicado: (2020)

Anti-cancer effects of newly developed chemotherapeutic agent, glycoconjugated palladium (II) complex, against cisplatin-resistant gastric cancer cells
por: Tanaka, Mamoru, et al.
Publicado: (2013)

Changes in 12-Year First-Line Eradication Rate of Helicobacter pylori Based on Triple Therapy with Proton Pump Inhibitor, Amoxicillin and Clarithromycin
por: Sasaki, Makoto, et al.
Publicado: (2010)

Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis
por: Kamm, M A, et al.
Publicado: (2008)

Real-World Long-Term Remission Maintenance for 10 Years With Thiopurines in Ulcerative Colitis
por: Matsumoto, Satohiro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r2as43a5ajgpvvk74upfjp9pqk